ArticleFrontiers in oncology2026

Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report.

Takuto Nosaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.